Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan 15;20(1):12.
doi: 10.1186/s12906-019-2803-2.

Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews

Affiliations
Review

Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews

Nadia Montero-Oleas et al. BMC Complement Med Ther. .

Abstract

Background: Although cannabis and cannabinoids are widely used with therapeutic purposes, their claimed efficacy is highly controversial. For this reason, medical cannabis use is a broad field of research that is rapidly expanding. Our objectives are to identify, characterize, appraise, and organize the current available evidence surrounding therapeutic use of cannabis and cannabinoids, using evidence maps.

Methods: We searched PubMed, EMBASE, The Cochrane Library and CINAHL, to identify systematic reviews (SRs) published from their inception up to December 2017. Two authors assessed eligibility and extracted data independently. We assessed methodological quality of the included SRs using the AMSTAR tool. To illustrate the extent of use of medical cannabis, we organized the results according to identified PICO questions using bubble plots corresponding to different clinical scenarios.

Results: A total of 44 SRs published between 2001 and 2017 were included in this evidence mapping with data from 158 individual studies. We extracted 96 PICO questions in the following medical conditions: multiple sclerosis, movement disorders (e.g. Tourette Syndrome, Parkinson Disease), psychiatry conditions, Alzheimer disease, epilepsy, acute and chronic pain, cancer, neuropathic pain, symptoms related to cancer (e.g. emesis and anorexia related with chemotherapy), rheumatic disorders, HIV-related symptoms, glaucoma, and COPD. The evidence about these conditions is heterogeneous regarding the conclusions and the quality of the individual primary studies. The quality of the SRs was moderate to high according to AMSTAR scores.

Conclusions: Evidence on medical uses of cannabis is broad. However, due to methodological limitations, conclusions were weak in most of the assessed comparisons. Evidence mapping methodology is useful to perform an overview of available research, since it is possible to systematically describe the extent and distribution of evidence, and to organize scattered data.

Keywords: Cannabinoids; Cannabis; Evidence mapping; Evidence synthesis; Medical marijuana.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flow chart outlining the study selection process
Fig. 2
Fig. 2
Methodological quality of included Systematic Reviews
Fig. 3
Fig. 3
Evidence mapping of cannabis uses in Multiple Sclerosis
Fig. 4
Fig. 4
Evidence mapping of cannabis uses in Movement Disorders, psychiatric conditions and other neurological disorders
Fig. 5
Fig. 5
Evidence mapping of cannabis use in pain
Fig. 6
Fig. 6
Evidence mapping of cannabis uses in Cancer
Fig. 7
Fig. 7
Evidence mapping of cannabis uses in other medical conditions

Similar articles

Cited by

References

    1. Whiting PF, Wolff RF, Deshpande S, Di NM, Duffy S, Hernandez AV, et al. Cannabinoids for medical use a systematic review and meta-analysis. JAMA. 2015;313(24):2456–2473. doi: 10.1001/jama.2015.6358. - DOI - PubMed
    1. Schrot RJ, Hubbard JR. Cannabinoids : Medical implications. Ann Med. 2016;48(3):128–141. doi: 10.3109/07853890.2016.1145794. - DOI - PubMed
    1. Bostwick JM. Blurred boundaries : the therapeutics and politics of medical marijuana. Mayo Clin Proc. 2012;87(2):172–186. doi: 10.1016/j.mayocp.2011.10.003. - DOI - PMC - PubMed
    1. Premoli M, Aria F, Bonini SA, Maccarinelli G, Gianoncelli A, Della Pina S, Tambaro S, Memo M, Mastinu A. Cannabidiol: recent advances and new insights for neuropsychiatric disorders treatment. Life Sci. 2019;224:120–127. doi: 10.1016/j.lfs.2019.03.053. - DOI - PubMed
    1. Kumar Amit, Premoli Marika, Aria Francesca, Bonini Sara Anna, Maccarinelli Giuseppina, Gianoncelli Alessandra, Memo Maurizio, Mastinu Andrea. Cannabimimetic plants: are they new cannabinoidergic modulators? Planta. 2019;249(6):1681–1694. doi: 10.1007/s00425-019-03138-x. - DOI - PubMed